Author Archives: admin


Stem Cell Clinic > Articles by: admin

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

By Global News Feed

FORT LEE, NJ, March 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference.

See original here:
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

Novelion Announces Completion of Plan of Liquidation and Distribution and its Voluntary Dissolution

By Global News Feed

VANCOUVER, British Columbia, March 10, 2023 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s liquidator (the “Liquidator”) today announced that Novelion has concluded the implementation of its plan of liquidation and distribution (the “Plan”) by winding down and dissolving the Company (the “Dissolution”).

Go here to read the rest:
Novelion Announces Completion of Plan of Liquidation and Distribution and its Voluntary Dissolution

Orchard Therapeutics Completes ADS Ratio Change

By Global News Feed

BOSTON and LONDON, March 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Company’s previously disclosed change to its American Depositary Share ("ADS") to ordinary share ratio has been made effective. The ratio has changed from one ADS to one ordinary share to the new ratio of one ADS to ten ordinary shares.

See the original post here:
Orchard Therapeutics Completes ADS Ratio Change

Chalice Brands Ltd. Announces Resignation of Board Member

By Global News Feed

PORTLAND, Ore., March 10, 2023 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE:CHAL) (OTCQB:CHALF) (the “Company” or “Chalice Brands”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, today announces that Mr. John Varghese has resigned from the Company’s Board of Directors (the “Board”) for personal reasons, effective immediately. Mr. Varghese was appointed to the Board on June 29, 2018 and served as Executive Chairman since September 2, 2019.

Follow this link:
Chalice Brands Ltd. Announces Resignation of Board Member

Medigene Amends 2022 Financial Guidance

By Global News Feed

MARTINSRIED, Germany and MUNICH, Germany, March 10, 2023 (GLOBE NEWSWIRE) -- The Executive Management Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today adjusted financial guidance for fiscal year 2022.

See the original post:
Medigene Amends 2022 Financial Guidance

Intelligent Bio Solutions Inc. Announces Closing of $2.55 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase…

By Global News Feed

NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced the closing of its previously announced underwritten public offering of 654,990 shares of common stock and warrants to purchase up to 196,497 shares of its common stock at a combined public offering price of $3.90 per share of common stock and accompanying warrants, which included the full exercise of the underwriter’s option to purchase up to 85,430 additional shares of common stock and additional warrants to purchase up to 25,629 shares of its common stock. Including the option exercise, the aggregate gross proceeds from the offering were approximately $2.55 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Originally posted here:
Intelligent Bio Solutions Inc. Announces Closing of $2.55 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase...

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

By Global News Feed

TEL AVIV, Israel, March 10, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced it has received a written notice (the “Notice”) from Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. The Notice has no immediate effect on the Company’s Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, the Company’s ordinary shares will continue to trade on Nasdaq under the symbol “SPRC”.

Read more here:
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

→←